<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Protalix Biotherapeutics, Inc. (de) — News on 6ix</title>
    <link>https://6ix.com/company/protalix-biotherapeutics-inc-de</link>
    <description>Latest news and press releases for Protalix Biotherapeutics, Inc. (de) on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 18 Mar 2026 10:50:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/protalix-biotherapeutics-inc-de" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d779b751cc36e47534025b.webp</url>
      <title>Protalix Biotherapeutics, Inc. (de)</title>
      <link>https://6ix.com/company/protalix-biotherapeutics-inc-de</link>
    </image>
    <item>
      <title>Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results</title>
      <link>https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-reports-fiscal-year-2025-financial-and-business-results</link>
      <guid isPermaLink="true">https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-reports-fiscal-year-2025-financial-and-business-results</guid>
      <pubDate>Wed, 18 Mar 2026 10:50:00 GMT</pubDate>
      <description>Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the fiscal year ended December 31, 2025, and provided a business and clinical update.</description>
    </item>
    <item>
      <title>Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026</title>
      <link>https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-to-announce-fiscal-year-2025-financial-results-and-business-update-on-march-18-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-to-announce-fiscal-year-2025-financial-results-and-business-update-on-march-18-2026</guid>
      <pubDate>Wed, 11 Mar 2026 10:50:00 GMT</pubDate>
      <description>Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the fiscal year ended December 31, 2025 and provide a business update on March 18, 2026.</description>
    </item>
    <item>
      <title>Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) ▼</title>
      <link>https://6ix.com/company/protalix-biotherapeutics-inc-de/news/chiesi-global-rare-diseases-and-protalix-biotherapeutics-announce-european-commission-approval-of-additional-dosing-regimen-of-every-four-weeks-for-elfabrior-pegunigalsidase-alfa</link>
      <guid isPermaLink="true">https://6ix.com/company/protalix-biotherapeutics-inc-de/news/chiesi-global-rare-diseases-and-protalix-biotherapeutics-announce-european-commission-approval-of-additional-dosing-regimen-of-every-four-weeks-for-elfabrior-pegunigalsidase-alfa</guid>
      <pubDate>Mon, 09 Mar 2026 12:30:00 GMT</pubDate>
      <description>Approved dosing regimen reduces the burden for eligible patients, their families, and the broader healthcare system by extending infusion interval from every-two-weeks to every-four-weeks for those stable with an enzyme replacement therapy (ERT) With this decision, announced ahead of Fabry Disease Awareness Month in April, Chiesi Global Rare Diseases will work with countries across the EU to support broader access to this additional dosing schedule for the adult Fabry community PARMA, Italy and</description>
    </item>
    <item>
      <title>Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU</title>
      <link>https://6ix.com/company/protalix-biotherapeutics-inc-de/news/chiesi-global-rare-diseases-and-protalix-biotherapeutics-receive-positive-chmp-opinion-for-an-additional-dosing-regimen-of-every-four-weeks-for-elfabrior-pegunigalsidase-alfa-in-the-eu</link>
      <guid isPermaLink="true">https://6ix.com/company/protalix-biotherapeutics-inc-de/news/chiesi-global-rare-diseases-and-protalix-biotherapeutics-receive-positive-chmp-opinion-for-an-additional-dosing-regimen-of-every-four-weeks-for-elfabrior-pegunigalsidase-alfa-in-the-eu</guid>
      <pubDate>Fri, 30 Jan 2026 14:47:00 GMT</pubDate>
      <description>Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2026 If approved by the EC, this dosing regimen would reduce the burden to eligible patients, their families, and the broader healthcare system due to the current requirement to visit infusion centres every two weeks for treatment This dosing regimen for Elfabrio is not approved in the U.S. In the U.</description>
    </item>
    <item>
      <title>Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU</title>
      <link>https://6ix.com/company/protalix-biotherapeutics-inc-de/news/chiesi-global-rare-diseases-and-protalix-biotherapeutics-receive-positive-chmp-opinion-for-an-additional-dosing-regimen-of-2mgkg-body-weight-every-four-weeks-for-elfabrior-pegunigalsidase-alfa-in-the-eu</link>
      <guid isPermaLink="true">https://6ix.com/company/protalix-biotherapeutics-inc-de/news/chiesi-global-rare-diseases-and-protalix-biotherapeutics-receive-positive-chmp-opinion-for-an-additional-dosing-regimen-of-2mgkg-body-weight-every-four-weeks-for-elfabrior-pegunigalsidase-alfa-in-the-eu</guid>
      <pubDate>Fri, 30 Jan 2026 14:47:00 GMT</pubDate>
      <description>Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2026 If approved by the EC, this dosing regimen would reduce the burden to eligible adult patients, their families and the broader healthcare system due to the current requirement to visit infusion centres or have home infusions every-2-weeks for treatment PARMA, Italy and CARMIEL, Israel, Jan. 30, 2</description>
    </item>
    <item>
      <title>Protalix BioTherapeutics Letter to Stockholders</title>
      <link>https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-letter-to-stockholders</link>
      <guid isPermaLink="true">https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-letter-to-stockholders</guid>
      <pubDate>Mon, 05 Jan 2026 11:50:00 GMT</pubDate>
      <description>Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced the following update from President and Chief Executive Officer, Dror Bashan, to its stockholders.</description>
    </item>
    <item>
      <title>PLX: Secarna’s Antisense Oligonucleotide Discovery Collaboration</title>
      <link>https://6ix.com/company/protalix-biotherapeutics-inc-de/news/plx-secarnas-antisense-oligonucleotide-discovery-collaboration</link>
      <guid isPermaLink="true">https://6ix.com/company/protalix-biotherapeutics-inc-de/news/plx-secarnas-antisense-oligonucleotide-discovery-collaboration</guid>
      <pubDate>Mon, 22 Dec 2025 07:15:00 GMT</pubDate>
      <description>By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Protalix BioTherapeutics, Inc. (NYSE:PLX) announced a collaboration with the Germany-based Secarna Pharmaceuticals to develop novel antisense oligonucleotide (ASO) therapies using Secarna’s OligoCreator platform. The arrangement will seek pharmaceutical candidates for rare renal indications. Details of the arrangement were</description>
    </item>
    <item>
      <title>Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement</title>
      <link>https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-and-secarna-pharmaceuticals-enter-into-collaboration-and-option-agreement</link>
      <guid isPermaLink="true">https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-and-secarna-pharmaceuticals-enter-into-collaboration-and-option-agreement</guid>
      <pubDate>Wed, 17 Dec 2025 11:50:00 GMT</pubDate>
      <description>Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, and Secarna Pharmaceuticals GmbH &amp; Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, today announced that they have entered into a collaboration and option agreement. Under this agreement, the companies have agreed t</description>
    </item>
    <item>
      <title>Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results</title>
      <link>https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-reports-third-quarter-2025-financial-and-business-results</link>
      <guid isPermaLink="true">https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-reports-third-quarter-2025-financial-and-business-results</guid>
      <pubDate>Thu, 13 Nov 2025 11:50:00 GMT</pubDate>
      <description>Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended September 30, 2025, and provided a financial and business update.</description>
    </item>
    <item>
      <title>Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025</title>
      <link>https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-to-announce-third-quarter-2025-financial-and-business-results-on-november-13-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-to-announce-third-quarter-2025-financial-and-business-results-on-november-13-2025</guid>
      <pubDate>Thu, 06 Nov 2025 11:50:00 GMT</pubDate>
      <description>Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended September 30, 2025 and provide a financial and business update on November 13, 2025.</description>
    </item>
    <item>
      <title>Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU</title>
      <link>https://6ix.com/company/protalix-biotherapeutics-inc-de/news/chiesi-global-rare-diseases-and-protalix-biotherapeutics-seek-re-examination-from-the-ema-for-the-negative-opinion-for-elfabrio-pegunigalsidase-alfa-alternative-dosing-regimen-of-every-four-weeks-in-the-eu</link>
      <guid isPermaLink="true">https://6ix.com/company/protalix-biotherapeutics-inc-de/news/chiesi-global-rare-diseases-and-protalix-biotherapeutics-seek-re-examination-from-the-ema-for-the-negative-opinion-for-elfabrio-pegunigalsidase-alfa-alternative-dosing-regimen-of-every-four-weeks-in-the-eu</guid>
      <pubDate>Mon, 03 Nov 2025 21:30:00 GMT</pubDate>
      <description>-- Every two weeks remains approved as a dosing regimen of Elfabrio in the EU --PARMA, Italy and CARMIEL, Israel, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group, and Protalix BioTherapeutics, Inc. (NYSE American: PLX), have requested a re-examination of the recent negative opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) regarding the proposed dosing regimen of 2 mg/kg body weigh</description>
    </item>
    <item>
      <title>Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU</title>
      <link>https://6ix.com/company/protalix-biotherapeutics-inc-de/news/chiesi-global-rare-diseases-and-protalix-biotherapeutics-acknowledge-chmp-negative-opinion-on-every-four-week-dosing-regimen-of-elfabrior-pegunigalsidase-alfa-in-the-eu</link>
      <guid isPermaLink="true">https://6ix.com/company/protalix-biotherapeutics-inc-de/news/chiesi-global-rare-diseases-and-protalix-biotherapeutics-acknowledge-chmp-negative-opinion-on-every-four-week-dosing-regimen-of-elfabrior-pegunigalsidase-alfa-in-the-eu</guid>
      <pubDate>Fri, 17 Oct 2025 10:58:00 GMT</pubDate>
      <description>Every two weeks remains approved as a dosing regimen of Elfabrio in the EUPARMA, Italy and CARMIEL, Israel, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, and Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its</description>
    </item>
    <item>
      <title>Protalix BioTherapeutics to Present at Investor Summit Virtual</title>
      <link>https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-to-present-at-investor-summit-virtual</link>
      <guid isPermaLink="true">https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-to-present-at-investor-summit-virtual</guid>
      <pubDate>Thu, 11 Sep 2025 14:55:00 GMT</pubDate>
      <description>CARMIEL, ISRAEL / ACCESS Newswire / September 11, 2025 / Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its ...</description>
    </item>
    <item>
      <title>Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference</title>
      <link>https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-to-present-at-the-hc-wainwright-27th-annual-global-investment-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-to-present-at-the-hc-wainwright-27th-annual-global-investment-conference</guid>
      <pubDate>Tue, 02 Sep 2025 10:50:00 GMT</pubDate>
      <description>Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that Dror Bashan, the Company&apos;s President and Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference which is being held on September 8–10, 2025 at the Lotte New York Palace Hot</description>
    </item>
    <item>
      <title>Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results</title>
      <link>https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-reports-second-quarter-2025-financial-and-business-results</link>
      <guid isPermaLink="true">https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-reports-second-quarter-2025-financial-and-business-results</guid>
      <pubDate>Thu, 14 Aug 2025 10:50:00 GMT</pubDate>
      <description>Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended June 30, 2025, and provided a business and clinical update.</description>
    </item>
    <item>
      <title>Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025</title>
      <link>https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-to-announce-second-quarter-2025-financial-and-business-results-on-august-14-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-to-announce-second-quarter-2025-financial-and-business-results-on-august-14-2025</guid>
      <pubDate>Thu, 07 Aug 2025 16:53:00 GMT</pubDate>
      <description>Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended June 30, 2025 and provide a business and clinical update on August 14, 2025.</description>
    </item>
    <item>
      <title>Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer</title>
      <link>https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-appoints-gilad-mamlok-as-its-new-senior-vice-president-and-chief-financial-officer</link>
      <guid isPermaLink="true">https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-appoints-gilad-mamlok-as-its-new-senior-vice-president-and-chief-financial-officer</guid>
      <pubDate>Mon, 21 Jul 2025 10:50:00 GMT</pubDate>
      <description>Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced the appointment of Gilad Mamlok to serve as the Company&apos;s new Senior Vice President and Chief Financial Officer, effective August 24, 2025, succeeding Eyal Rubin. To ensure a seamless transition, Mr. Mamlok has joined the c</description>
    </item>
    <item>
      <title>Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®</title>
      <link>https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-added-to-russell-3000r-and-2000-indexesr</link>
      <guid isPermaLink="true">https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-added-to-russell-3000r-and-2000-indexesr</guid>
      <pubDate>Mon, 30 Jun 2025 10:50:00 GMT</pubDate>
      <description>Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced the Company has been added to the Russell 3000® and Russell 2000® Indexes, effective as of the U.S. market close on June 27, 2025, as part of the 2025 Russell indexes annual reconstitution.</description>
    </item>
    <item>
      <title>Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC</title>
      <link>https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-to-present-at-the-3rd-annual-hc-wainwright-bioconnect-investor-conference-at-nasdaq-nyc</link>
      <guid isPermaLink="true">https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-to-present-at-the-3rd-annual-hc-wainwright-bioconnect-investor-conference-at-nasdaq-nyc</guid>
      <pubDate>Wed, 14 May 2025 10:50:00 GMT</pubDate>
      <description>Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference, taking place on Tuesday, May 20, 2025 at the Nasdaq headquarters in New York City, New York.</description>
    </item>
    <item>
      <title>Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results</title>
      <link>https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-reports-first-quarter-2025-financial-and-business-results</link>
      <guid isPermaLink="true">https://6ix.com/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-reports-first-quarter-2025-financial-and-business-results</guid>
      <pubDate>Fri, 09 May 2025 10:50:00 GMT</pubDate>
      <description>Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2025, and provided a business and clinical update.</description>
    </item>
  </channel>
</rss>